Lung Cancer Screening, Towards a Multidimensional Approach: Why and How?

Area of Science:

• Oncology
• Radiology
• Biomarkers

Background:

• Early-stage lung cancer treatment significantly improves patient prognosis.
• Low-dose computed tomography (LDCT) has demonstrated mortality reduction in lung cancer screening (LCS).
• Current LCS faces challenges including high false-positive rates and radiologist shortages, leading to clinic overload.

Purpose of the Study:

• To review methods for improving LDCT-based lung cancer screening.
• To address the need for reduced false-positive rates in current lung cancer detection technology.
• To enhance early access to life-saving surgical interventions for lung cancer patients.

Main Methods:

• Review of strategies to refine lung cancer screening.
• Discussion of improved patient selection criteria based on risk factor assessment.
• Exploration of Computer Aided Diagnosis (CAD) for enhanced chest CT interpretation.
• Evaluation of biological blood signatures for early cancer detection and nodule classification.

Main Results:

• LDCT-based LCS shows promise in reducing lung cancer mortality.
• High false-positive rates in LDCT currently challenge screening efficiency.
• Potential exists to improve LCS through refined selection, CAD, and blood biomarkers.

Conclusions:

• Improving lung cancer screening is crucial for early intervention and better patient outcomes.
• A multi-pronged approach involving risk assessment, CAD, and biomarkers can optimize LCS.
• Addressing false positives is key to making LCS more efficient and accessible.